1. Introduction {#sec1}
===============

Ovarian cancer is one of the most common cancers in women worldwide. The standard first-line treatment is chemotherapy with platinum and taxane agents, and the majority of cases respond well to this treatment \[[@B1], [@B2]\]. However, most cases experienced relapse and became resistant to platinum and subsequent chemotherapeutic agents \[[@B2]\]. Recent studies have demonstrated that immune checkpoint blockade therapy is very effective for the treatment of melanoma and non-small-cell lung cancer, although these dramatic clinical effects were observed in only 20--30% of patients \[[@B3]--[@B5]\]. Promising results of immune checkpoint blockade therapy have also been reported in ovarian cancer \[[@B6]\].

We previously reported a clinical study of personalized peptide vaccination (PPV) for recurrent ovarian cancer patients, in which the vaccine peptides were selected from a peptide panel consisting of 31 cytotoxic T-lymphocyte- (CTL-) epitope peptides based on preexisting host immunity before vaccination \[[@B7]\]. In that study, we analyzed the relationship of several immune-related or inflammation-related biomarkers with the prognosis of patients and circulating lymphocyte frequency at prevaccination, and epitope spreading after the 1st cycle of vaccination was found to be significantly prognostic of overall survival (OS) \[[@B7]\]. However, other biomarkers were not prognostic or predictive. Therefore, the exploration of new biomarkers for cancer vaccine will be important.

High-mobility group box 1 (HMGB1) is a nuclear protein that is known to be secreted into plasma and other extracellular fluids from injured cells, activated macrophages, and tumor cells \[[@B8]--[@B11]\]. Circulating HMGB1 levels have been clinically and pathologically correlated with various diseases, including cancer \[[@B12]\]. However, there is no information on HMGB1 levels in cancer patients treated with peptide vaccination. In the present study, therefore, we investigated the plasma levels of HMGB1 during PPV in patients with recurrent ovarian cancer.

2. Materials and Methods {#sec2}
========================

2.1. Plasma Samples {#sec2.1}
-------------------

Frozen plasma samples that had been collected from 39 patients with recurrent ovarian cancer who were treated with PPV in previously conducted clinical trials and stored at −80°C were used in this study. The protocols of the clinical trials, including protocols for the measurement of plasma biomarkers, were approved by the Kurume University Ethics Committee and registered with the UMIN Clinical Trial Registry under trial numbers [UMIN000003083](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000003745) and [UMIN000001482](https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000001740). One vaccination cycle consisted of once a week vaccination for six consecutive weeks.

Plasma HMGB1 levels were measured by using an HMGB1 ELISA kit II (Shino-Test, Sagamihara, Japan) according to the manufacturer\'s instructions. The detection limit was 2.5 ng/mL in our system.

2.2. Statistical Analysis {#sec2.2}
-------------------------

The statistical analyses were performed using JMP Pro version 12 software (SAS Institute, Cary, NC). Changes in the HMGB1 levels between prevaccination and postvaccination samples were analyzed by paired *t*-test. The correlation between HMGB1 levels and OS was analyzed by log-rank test. The comparisons between plasma HMGB1 levels and other biomarkers were analyzed by *t*-test and chi-square test.

3. Results {#sec3}
==========

3.1. Plasma Levels of HMGB1 during Peptide Vaccination {#sec3.1}
------------------------------------------------------

Frozen plasma samples of 39 patients with recurrent ovarian cancer who had been treated with PPV in clinical trials were used in this study. The HMGB1 levels after the 1st cycle of vaccination (postvaccination) (4.63 ± 3.25 ng/mL) were significantly lower than the prevaccination values (5.96 ± 3.69 ng/mL) (*p* = 0.043) ([Figure 1](#fig1){ref-type="fig"}). The 39 patients consisted of patients with serous adenocarcinoma (*n* = 21), endometrioid carcinoma (*n* = 7), clear-cell carcinoma (*n* = 3), mucinous adenocarcinoma (*n* = 3), squamous cell carcinoma (*n* = 1), undifferentiated malignant tumor (*n* = 2), and others (*n* = 2). The patients were divided into two groups, that is, serous type (*n* = 21) and nonserous type (*n* = 18), for subgroup analyses. Prevaccination HMGB1 levels of the serous and nonserous types were, respectively, 5.87 ± 3.69 ng/mL and 6.07 ± 3.79 ng/mL, and those of the postvaccination group were 5.16 ± 3.75 ng/mL and 4.00 ± 2.50 ng/mL, respectively. Therefore, the significant decrease in HMGB1 levels after the 1st cycle of vaccination found in the overall group of 39 patients was confirmed in the non-serous-type group (*n* = 18, *p* = 0.043) but not in the serous type group.

3.2. Relationship between HMGB1 Levels and Overall Survival {#sec3.2}
-----------------------------------------------------------

Patients were divided into high-HMGB1 group and low-HMGB1 group according to whether their pre- or postvaccination levels of plasma HMGB1 were higher or lower than the median value. Patients were also divided into a decreased or a not-decreased group according to the changes between their pre- and postvaccination values, and the correlations between these groups and OS were analyzed by Kaplan-Meier plot analysis ([Figure 2](#fig2){ref-type="fig"}). No significant correlations were found between the plasma HMGB1 levels and OS in either the pre- or postvaccination samples (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}, resp.). Changes of plasma HMGB1 levels were similarly not a significant prognostic factor in OS ([Figure 2(c)](#fig2){ref-type="fig"}). It is noted that 20% of patients belonged to the low-HMGB1 prevaccination group and that 25% of the not-decreased group were long-term survivors with \>37 months of OS.

3.3. Comparison between Plasma HMGB1 Levels and Other Biomarkers {#sec3.3}
----------------------------------------------------------------

In our previous analysis of this clinical study, we reported that epitope spreading after the 1st cycle of vaccination was a significant prognostic factor correlated to OS \[[@B7]\]. The other markers used in the previous study were as follows: IgG and CTL responses to the vaccinated peptides, frequency of circulating myeloid-derived suppressor cells (MDSCs), plasma levels of serum amyloid A (SAA), C-reactive protein (CRP), and interleukin-6 (IL-6). MDSCs in the peripheral blood were defined as CD33^+^ CD3^−^ CD14^−^ CD19^−^ CD56^−^ HLA-DR^−^ cells \[[@B7]\]. Gating strategy for the identification of MDSCs is shown in [Figure 3](#fig3){ref-type="fig"}. HMGB1 levels and previously measured data of the biomarker levels are shown in [Table 1](#tab1){ref-type="table"}. Precise data of IgG and CTL responses and epitope spreading were previously published, and thus, these results are only summarized in [Table 1](#tab1){ref-type="table"}. Correlations between the plasma HMGB1 levels and the other biomarker levels were analyzed by scatter plot. The postvaccination HMGB1 levels were significantly correlated with the postvaccination MDSC frequency (*r* = 0.357, *p* = 0.032) but not with the postvaccination values of SAA, CRP, or IL-6 ([Figure 4](#fig4){ref-type="fig"}). Prevaccination values or changes between the pre- and postvaccination values of HMGB1 were not correlated with the corresponding values of SAA, CRP, or IL-6 (data not shown).

Changes of plasma HMGB1 levels were categorized into three groups, an increase, a decrease, and a no-change group. Similarly, changes in each of the other biomarkers were categorized as simply "yes" or "no" ([Table 2](#tab2){ref-type="table"}). The proportions of the categories of HMGB1 and the other biomarkers were compared by chi-square test. The results showed that epitope spreading was significantly related with changes of HMGB1 (*p* = 0.030) and that IgG and CTL responses, MDSC, SAA, CRP, and IL-6 were independent of HMGB1.

4. Discussion {#sec4}
=============

HMGB1 is a representative member of the damage-associated molecular patterns (DAMPs), also called alarmins, which are molecules released from necrotic cells as intrinsic danger signals which induce inflammation and trigger innate immunity \[[@B8]\]. Toll-like receptor (TLR) 2 or 4 and receptor for advanced glycation end products (RAGE) are known to be receptors of HMGB1 \[[@B13], [@B14]\]. In addition to the role of initiator of innate immunity, HMGB1 also exerts an immunosuppressive effect through the T cell immunoglobulin domain and mucin domain 3 (TIM3), an immune checkpoint molecule on activated T cells \[[@B15]\]. Recently, we found that HMGB1 inhibitors, such as glycyrrhizin, exhibited an immunopotentiating effect in combination with an innate immunity receptor-related adjuvant in a murine peptide vaccine model \[[@B16]\]. These facts indicate that HMGB1 has two opposite functions, that is, it both initiates and suppresses immunity.

Circulating HMGB1 levels have been clinically and pathologically correlated with various diseases, including cancer \[[@B12], [@B17]\]. High levels of HMGB1 have been correlated with worsened disease outcome in most types of cancers, including colorectal cancer, bladder cancer, and hepatocellular carcinoma \[[@B12]\]. However, the opposite results were also obtained in some cancers---namely, high levels of HMGB1 were correlated with better prognosis in patients with esophageal cancer and gastric cancer \[[@B12]\]. These results were obtained from patients in various clinical settings, although none were undergoing immune therapy. In fact, to our knowledge, there has been only one report on the HMGB1 levels of patients treated with immunotherapy: Gebhardt et al. \[[@B18]\] reported the possibility of circulating HMGB1 as a novel predictive marker for melanoma patients who may benefit from ipilimumab (anti-CTLA-4 antibody) therapy. In the present study, therefore, we investigated the plasma levels of HMGB1 in patients with ovarian cancer treated with peptide vaccination. The presence of circulating HMGB1 in patients with ovarian cancer has been reported, and the levels were significantly higher than those in patients with benign ovarian tumors or healthy donors, and the levels in recurrent patients were higher than those in nonrecurrent patients \[[@B19], [@B20]\].

In the present study, plasma HMGB1 levels were decreased after the 1st cycle of vaccination ([Figure 1](#fig1){ref-type="fig"}). The most plausible mechanism of this decrease in HMGB1 is that the tumor mass was reduced by vaccination. However, in most of the cases studied, the best clinical response was progressive disease \[[@B7]\], and thus, it was hard to confirm that such a mechanism was operative. Further accumulation and analysis of biomarkers may clarify whether this mechanism plays a role. Approximately 20--25% of patients belonging to the group with low prevaccination HMGB1 or the not-decreased group were long-term survivors with \>37 months of OS ([Figure 2](#fig2){ref-type="fig"}). These results may suggest that HMGB1 could be used as a predictive and/or prognostic marker of peptide vaccination. We also found that postvaccination plasma HMGB1 levels were significantly correlated with the post-MDSC frequency ([Figure 3](#fig3){ref-type="fig"}). It is known that chronic inflammation facilitates malignancy by inducing the accumulation and increasing the potency of MDSCs \[[@B21]\]. HMGB1 is an initiator of inflammation and has been reported to play a role in the development of MDSCs \[[@B22]\]. CCL2, a member of C-C chemokine family, is known as a major cytokine for the recruitment of myeloid cells including MDSCs from the bone marrow to cancer tissues \[[@B23], [@B24]\], and induction of CCL2 in various cells by HMGB1 has also been reported \[[@B25], [@B26]\]. These facts support our findings. Epitope spreading has been reported as an immune response-related prognostic marker of good outcome in our previous analysis of this clinical trial \[[@B7]\]. Epitope spreading was not observed in the cases with increased HMGB1 in this study. Thus, epitope spreading might be due to the suppression of immune responses by MDSCs induced by HMGB1.

5. Conclusion {#sec5}
=============

Our present data suggest that plasma HMGB1 may be a predictive and/or prognostic marker for cancer vaccine therapy, although at the present time, there remains no direct correlation with OS. Future clinical studies on the circulating HMGB1 levels in large numbers of patients will be needed to clarify the usefulness of HMGB1 in immunotherapy.
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![Plasma levels of HMGB1 during peptide vaccination. Plasma HMGB1 levels of pre- and post-1st cycle vaccination samples of the total 39 cases (a), the 21 serous-type cases (b), and the 18 non-serous-type cases (c) are shown. ns: Not significant.](JIR2017-1423683.001){#fig1}

![The relationship between plasma HMGB1 levels and overall survival (OS) was analyzed by Kaplan-Meier plot analysis. Patients (*n* = 39) were divided into high and low plasma HMGB1 groups based on the (a) pre- and (b) postvaccination levels, and the correlation between these subgroups and OS was analyzed. (c) Patients (*n* = 39) were also divided into decreased and not-decreased groups based on the changes of plasma HMGB1 between the prevaccination and postvaccination samples, and the relation between these subgroups and OS was plotted.](JIR2017-1423683.002){#fig2}

![Gating strategy for the identification of MDSCs in the peripheral blood of patients. PBMCs were stained with anti-CD3-FITC, anti-CD19-FITC, anti-CD56-FITC, anti-CD33-APC, anti-HLA-DR-PE/Cy7, and anti-CD14-APC/Cy7 Abs. In the cell subset negative for the lineage markers (CD3, CD19, CD56, and CD14) and HLA-DR, MDSCs were identified as CD33^+^.](JIR2017-1423683.003){#fig3}

![Correlations between postvaccination plasma HMGB1 levels and postvaccination levels of MDSC frequency, SAA, CRP, or IL-6 were analyzed by scatter plot.](JIR2017-1423683.004){#fig4}

###### 

HMGB1 and other biomarkers of patients with ovarian cancer treated with peptide vaccination^†^.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case      Overall survival\   IgG response   CTL response   Epitope spreading   HMGB1^‡^\   MDSC^‡^ (%)   SAA^‡^ (mg/dL)   CRP^‡^ (mg/dL)   IL-6^‡^ (pg/mL)                                                              
            (months)                                                              (ng/mL)                                                                                                                                  
  --------- ------------------- -------------- -------------- ------------------- ----------- ------------- ---------------- ---------------- ----------------- -------- ------ ------ ---- ----- ----- ---- ------ ------ ----
  F-018     19.1                No             No             No                  \<2.5       2.7           NC               0.3              0.6               I        10.5   5.2    D    0.3   0.4   NC   2      11     I

  FOV-003   20.0                Yes            Yes            Yes                 5.9         \<2.5         D                0.2              0.3               NC       1.5    19.5   I    0.0   0.9   I    0      0      NC

  FOV-004   5.3                 Yes            Yes            Yes                 10.6        \<2.5         D                0.6              0.5               NC       3.2    11.6   I    0.1   0.3   I    2      3      NC

  FOV-005   11.4                Yes            Yes            Yes                 5.7         \<2.5         D                0.6              0.5               NC       0.4    12.7   I    0.2   0.8   I    0      2      I

  FOV-006   34.7                Yes            Yes            Yes                 \<2.5       2.9           NC               0.5              0.5               NC       0.7    1.1    NC   0.1   0.2   I    0      0      NC

  FOV-008   14.1                Yes            Yes            No                  4.3         2.8           NC               0.1              0.1               NC       2.4    18.8   I    0.1   0.9   I    0      0      NC

  FOV-009   8.1                 Yes            Yes            Yes                 4.5         3.9           NC               0.5              0.4               NC       20.4   20.8   NC   0.7   1.0   NC   0      0      NC

  FOV-010   \>69.7              Yes            Yes            Yes                 \<2.5       \<2.5         NC               0.1              0.3               I        0.3    7.9    I    0.0   0.5   I    0      0      NC

  FOV-012   16.1                Yes            Yes            No                  \<2.5       \<2.5         NC               1.1              1.6               NC       6.3    1.7    D    0.1   0.5   I    0      0      NC

  FOV-013   4.0                 No             Yes            No                  \<2.5       3.7           NC               0.1              0.1               NC       11.8   11.8   NC   0.9   0.9   NC   10     23     I

  FOV-014   32.2                Yes            Yes            Yes                 5.0         3.5           NC               0.3              0.3               NC       12.8   14.8   NC   0.1   0.3   I    0      0      NC

  FOV-015   10.7                Yes            No             No                  4.0         10.4          I                1                1.2               NC       2.9    14.9   I    0.6   0.9   NC   0      0      NC

  FOV-016   29.5                Yes            Yes            No                  3.8         9.2           I                0.6              0.4               NC       12.1   13.8   NC   1.0   0.9   NC   6      12     I

  FOV-019   \>61.3              Yes            No             Yes                 2.7         4.9           NC               0.6              0.4               NC       1.4    5.6    I    0.1   0.6   I    0      0      NC

  FOV-022   22.0                Yes            Yes            No                  4.6         3.2           NC               0.5                                ---^§^   1.8    3.6    I    0.4   0.1   D    0      0      NC

  FOV-023   16.8                Yes            Yes            Yes                 6.5         3.5           NC               0.1              0.2               I        13.8   11.9   NC   1.5   2.3   NC   2      15     I

  FOV-024   8.7                 No             No             No                  \<2.5       6.1           I                0.2              0.1               D        8.9    11.8   NC   0.8   2.3   I    0      17     I

  FOV-026   \>45.7              Yes            Yes            Yes                 3.1         5.2           NC                                                  NC       4.2    5.5    NC   0.1   0.1   NC   0      0      NC

  FOV-027   36.9                Yes            Yes            Yes                 12.8        7.8           NC               0.2              0.6               I        2.6    4.8    NC   0.0   0.6   I    0      0.5    I

  FOV-028   \>42.7              Yes            Yes            No                  17.4        \<2.5         D                0.2              0.7               I        0.3    0.4    NC   0.3   0.0   D    1.2    1.1    NC

  FOV-030   22.0                Yes            Yes            Yes                 8.5         12.5          NC               0.4              0.5               NC       6.1    22.5   I    0.4   4.1   I    0      8      I

  FOV-031   19.6                Yes            No             Yes                 4.2         4.7           NC               0.3              0.3               NC       8.2    9.5    NC   0.1   0.2   I    0      0      NC

  FOV-032   12.6                Yes            Yes            Yes                 4.2         3.8           NC               0.6              0.3               D        0.3    5.2    I    0.2   2.2   I    0      7.2    I

  FOV-033   26.9                Yes            Yes            Yes                 \<2.5       3.5           NC               0.4              0.5               NC       1.6    12.9   I    0.1   1.8   I    0      2.7    I

  FOV-034   26.8                Yes            No             Yes                 12.2        6.7           NC               0.7              0.6               NC       0.6    0.7    NC   0.1   0.3   I    0      0      NC

  FOV-036   24.0                Yes            Yes            Yes                 5.4         4.2           NC               0.2              0.2               NC       1.8    19.3   I    1.9   4.4   I    0.9    26.2   I

  FOV-037   4.6                 No             No             No                  7.3         2.6           D                0.7              0.4               NC       0.7    15.8   I    1.4   4.4   I    4.6    19.8   I

  FOV-038   7.9                 No             No             No                  15.1        18.6          NC               1.4              1.1               NC       11.6   20.9   NC   1.7   3.6   I    4.5    14.9   I

  FOV-039   \>10.3              Yes            No             No                  3.0         \<2.5         NC                                                  ---^§^   0.9    1.3    NC   0.4   0.7   NC   0      1.6    I

  FOV-040   2.2                 No             No             No                  6.1         \<2.5         D                0.8              0.6               NC       14.1   15.5   NC   1.0   1.8   NC   3.9    7.2    NC

  FOV-041   18.3                Yes            No             Yes                 8.6         3.6           D                0.8              0.5               NC       2.1    2.3    NC   0.1   0.1   NC   0      0      NC

  FOV-042   \>37                Yes            No             No                  4.0         4.0           NC               0.3              0.1               D        0.3    0.4    NC   0.1   0.1   NC   0      0      NC

  FOV-043   29.2                Yes            Yes            Yes                 2.9         4.6           NC               0.2              0.3               NC       13.4   1.3    D    2.0   0.3   D    12.5   0      D

  FOV-044   19.6                Yes            Yes            Yes                 10.4        2.9           D                0.1              0.2               I        1.0    10.1   I    0.0   1.3   I    0      0      NC

  FOV-045   8.3                 Yes            Yes            Yes                 6.3         5.5           NC               0.2              0.3               NC       1.6    18.8   I    0.7   3.6   I    1.8    10.7   I

  FOV-046   6.6                 Yes            Yes            No                  3.7         \<2.5         NC               0.3              0.1               D        21.0   16.0   NC   3.8   4.1   NC   11.4   17.1   NC

  FOV-047   \>35.5              Yes            Yes            Yes                 8.7         3.8           D                0.5              0.8               NC       6.3    1.6    D    0.4   0.2   D    16.3   1.4    D

  FOV-048   4.7                 Yes            No             No                  7.0         \<2.5         D                0.5              0.3               NC       21.9   18.3   NC   3.9   4.9   NC   2.1    17.6   I

  FOV-049   22.0                Yes            No             Yes                 6.6         4.8           NC               1                0.7               NC       4.2    2.6    NC   0.2   0.4   I    0      0      NC
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^ ^‡^ ^§^Blood samples of patients were collected before (pre) and after (post) the 1st cycle of vaccination, and HMGB1 and other biomarkers were measured. Response criteria of IgG, CTL, and epitope spreading were previously reported; post values were compared with prevalues, and if the postvalue was ≥150% or ≤50% of prevalue, it was considered increased or decreased, respectively. I: increased; D: decreased; NC: no change; samples were not available.

###### 

Comparison of HMGB1 and other biomarkers.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           IgG\       CTL\       Epitope\    MDSC\      SAA\       CRP\        IL-6\                                                            
                           response   response   spreading   increase   increase   increase    increase                                                         
  ------------------------ ---------- ---------- ----------- ---------- ---------- ----------- ---------- ---------- ---------- ---------- ----- -------- ----- --------
  HMGB1 increase (I)       Yes        2          Yes         1          Yes        0           Yes        0          Yes        1          Yes   1        Yes   2

                           No         1          No          2          No         3           No         3          No         2          No    2        No    1

  HMGB1 no change (NC)     Yes        23         Yes         18         Yes        17          Yes        4          Yes        9          Yes   16       Yes   11

                           No         3          No          8          No         9           No         20         No         17         No    10       No    15

  HMGB1 decrease (D)       Yes        8          Yes         6          Yes        6           Yes        2          Yes        5          Yes   5        Yes   3

                           No         2          No          4          No         4           No         8          No         5          No    5        No    7

  *p* value^†^                                                                                                                                                  

   I versus not I (NC+D)              0.3698                 0.2475                0.0307^∗^              0.4267                0.8493           0.4015         0.3473

   D versus not D (NC+I)              0.639                  0.7538                0.939                  0.7039                0.3844           0.6355         0.4111

                                                                                                                                                                

                                                                                               MDSC\      SAA\       CRP\       IL-6\                           
                                                                                               decrease   decrease   decrease   decrease                        

                                                                                               *n* = 37   *n* = 39   *n* = 39   *n* = 39                        

                                                                                                          *n*                   *n*              *n*            *n*

                                                                                                                                                                

  HMGB1 increase (I)                                                                           Yes        1          Yes        0          Yes   0        Yes   0

                                                                                               No         2          No         3          No    3        No    3

  HMGB1 no change (NC)                                                                         Yes        3          Yes        3          Yes   2        Yes   1

                                                                                               No         21         No         23         No    24       No    25

  HMGB1 decrease (D)                                                                           Yes        0          Yes        1          Yes   2        Yes   1

                                                                                               No         10         No         9          No    8        No    9

  *p* value                                                                                                                                                     

   I versus not I (NC+D)                                                                                  0.19                  0.5422           0.5422         0.6751

   D versus not D (NC+I)                                                                                  0.1975                0.9753           0.2389         0.418
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^ ^∗^ *p* values of chi-square test are shown; statistically significant.

[^1]: Academic Editor: Shahab Uddin
